Elefante Mark B bought a new stake in shares of Danaher Corporation (NYSE:DHR – Free Report) in the second quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor bought 28,204 shares of the conglomerate’s stock, valued at approximately $5,372,000. Danaher comprises approximately 2.3% of Elefante Mark B’s holdings, making the stock its 19th largest position.
Several other institutional investors have also added to or reduced their stakes in DHR. EP Wealth Advisors LLC purchased a new stake in Danaher in the second quarter worth about $3,807,000. Northwestern Mutual Wealth Management Co. lifted its position in shares of Danaher by 303.7% during the 4th quarter. Northwestern Mutual Wealth Management Co. now owns 248,020 shares of the conglomerate’s stock valued at $56,777,000 after buying an additional 186,584 shares in the last quarter. Puzo Michael J bought a new position in shares of Danaher during the 2nd quarter valued at approximately $8,624,000. Legal & General Group Plc grew its stake in shares of Danaher by 1.0% during the 4th quarter. Legal & General Group Plc now owns 4,495,287 shares of the conglomerate’s stock valued at $1,029,061,000 after acquiring an additional 43,169 shares during the period. Finally, Madison Asset Management LLC purchased a new stake in Danaher in the 2nd quarter worth approximately $85,451,000. 79.05% of the stock is currently owned by institutional investors.
Analyst Upgrades and Downgrades
A number of equities research analysts have commented on DHR shares. Piper Sandler initiated coverage on shares of Danaher in a research note on Thursday, June 11th. They set a “neutral” rating and a $200.00 target price on the stock. Guggenheim dropped their price target on shares of Danaher from $235.00 to $200.00 and set a “buy” rating for the company in a research report on Wednesday, July 22nd. Stifel Nicolaus reduced their price objective on shares of Danaher from $260.00 to $220.00 and set a “buy” rating for the company in a research note on Wednesday, July 22nd. TD Cowen decreased their price objective on shares of Danaher from $240.00 to $236.00 and set a “buy” rating on the stock in a research report on Wednesday, July 22nd. Finally, HSBC lowered their target price on shares of Danaher from $270.00 to $230.00 and set a “buy” rating on the stock in a research note on Wednesday, June 3rd. One investment analyst has rated the stock with a Strong Buy rating, nineteen have given a Buy rating and five have assigned a Hold rating to the stock. According to MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $228.91.
Danaher Trading Up 0.3%
DHR stock opened at $219.42 on Monday. The company has a debt-to-equity ratio of 0.48, a current ratio of 1.65 and a quick ratio of 1.25. Danaher Corporation has a 1-year low of $160.93 and a 1-year high of $242.80. The business has a 50 day simple moving average of $195.80 and a two-hundred day simple moving average of $192.40. The company has a market capitalization of $154.25 billion, a price-to-earnings ratio of 38.97, a PEG ratio of 2.72 and a beta of 0.78.
Danaher (NYSE:DHR – Get Free Report) last released its quarterly earnings data on Monday, July 20th. The conglomerate reported $1.94 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.85 by $0.09. Danaher had a net margin of 15.95% and a return on equity of 11.04%. The firm had revenue of $6.26 billion for the quarter, compared to analysts’ expectations of $6.12 billion. During the same quarter last year, the business posted $0.77 earnings per share. The company’s revenue for the quarter was up 5.5% compared to the same quarter last year. Research analysts anticipate that Danaher Corporation will post 8.53 EPS for the current fiscal year.
Danaher Profile
Danaher Corporation (NYSE: DHR) is a global science and technology company that designs, manufactures and markets products and services for the life sciences, diagnostics, and environmental and applied markets. The company organizes its operations into business segments focused on Life Sciences, Diagnostics, and Environmental & Applied Solutions, supplying instruments, reagents, software and related services that support research, clinical testing, biopharmaceutical development, and industrial and environmental monitoring.
Products and services in Danaher’s portfolio include analytical and diagnostic instruments, laboratory consumables and reagents, digital and software solutions for workflow and data management, field and industrial monitoring equipment, and service and maintenance programs.
Read More
- Five stocks we like better than Danaher
- VIG, VYM, and VYMI: Which Vanguard Dividend ETF Is Right for You?
- 3 Closed-End Funds to Maximize Dividend Payments
- Rocket Lab’s Sell-Off Is Fading—Is It Finally Safe to Buy?
- $27 Billion in Buybacks: 3 Stocks Betting Their Strong Runs Aren’t Over
Want to see what other hedge funds are holding DHR? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Danaher Corporation (NYSE:DHR – Free Report).
Receive News & Ratings for Danaher Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Danaher and related companies with MarketBeat.com's FREE daily email newsletter.
